Aptevo Therapeutics (APVO) Competitors $1.70 -0.09 (-5.03%) Closing price 04:00 PM EasternExtended Trading$1.73 +0.03 (+1.76%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO vs. PPBT, NKGN, HCWB, THAR, VYNE, KTTA, AEZS, SPRB, BCTX, and CDTShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Purple Biotech (PPBT), NKGen Biotech (NKGN), HCW Biologics (HCWB), Tharimmune (THAR), VYNE Therapeutics (VYNE), Pasithea Therapeutics (KTTA), Aeterna Zentaris (AEZS), Spruce Biosciences (SPRB), Briacell Therap (BCTX), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Its Competitors Purple Biotech NKGen Biotech HCW Biologics Tharimmune VYNE Therapeutics Pasithea Therapeutics Aeterna Zentaris Spruce Biosciences Briacell Therap Conduit Pharmaceuticals Aptevo Therapeutics (NASDAQ:APVO) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk. Which has stronger valuation & earnings, APVO or PPBT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo TherapeuticsN/AN/A-$24.13MN/AN/APurple BiotechN/AN/A-$7.24M-$0.42-5.40 Do analysts rate APVO or PPBT? Aptevo Therapeutics currently has a consensus target price of $219,040.00, indicating a potential upside of 12,884,605.88%. Purple Biotech has a consensus target price of $33.00, indicating a potential upside of 1,353.74%. Given Aptevo Therapeutics' higher probable upside, equities research analysts clearly believe Aptevo Therapeutics is more favorable than Purple Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in APVO or PPBT? 8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 0.0% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to APVO or PPBT? In the previous week, Purple Biotech had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.88 beat Purple Biotech's score of 0.93 indicating that Aptevo Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aptevo Therapeutics Very Positive Purple Biotech Positive Which has more volatility & risk, APVO or PPBT? Aptevo Therapeutics has a beta of 5.64, suggesting that its share price is 464% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Is APVO or PPBT more profitable? Purple Biotech's return on equity of -14.00% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -675.52% -175.68% Purple Biotech N/A -14.00%-12.52% SummaryPurple Biotech beats Aptevo Therapeutics on 6 of the 9 factors compared between the two stocks. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.89M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.0831.2626.59Price / SalesN/A364.13454.13168.41Price / CashN/A44.6737.7359.36Price / Book0.868.0910.046.68Net Income-$24.13M-$54.08M$3.27B$265.59M7 Day Performance-17.87%2.25%3.17%3.42%1 Month Performance-42.18%3.41%4.34%1.09%1 Year Performance-99.98%18.61%44.12%23.84% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics3.3593 of 5 stars$1.70-5.0%$219,040.00+12,884,605.9%-100.0%$5.89MN/A0.0050Positive NewsGap UpHigh Trading VolumePPBTPurple Biotech1.8476 of 5 stars$2.27-1.7%$33.00+1,353.7%N/A$5.97MN/A-5.4020News CoverageGap DownNKGNNKGen BiotechN/A$0.13-5.4%N/A-80.7%$5.96MN/A-0.03N/AHCWBHCW Biologics2.5126 of 5 stars$4.02-1.7%$35.00+770.6%-68.0%$5.89M$2.57M-0.1740Gap UpTHARTharimmune3.4424 of 5 stars$1.30-3.7%$17.00+1,207.7%+68.1%$5.70MN/A-0.212VYNEVYNE Therapeutics2.543 of 5 stars$0.34-1.9%$6.25+1,716.9%-81.9%$5.34M$500K-0.3830Gap DownKTTAPasithea Therapeutics1.0847 of 5 stars$0.71+1.2%N/A-83.7%$5.23MN/A-0.093News CoveragePositive NewsGap UpAEZSAeterna ZentarisN/A$2.85-18.6%N/A-24.2%$5.11M$2.37M-0.1920Gap DownHigh Trading VolumeSPRBSpruce Biosciences1.7008 of 5 stars$9.01+3.0%$131.25+1,356.7%-78.8%$5.06M$4.91M-9.5920BCTXBriacell Therap2.8184 of 5 stars$0.76+3.1%$32.00+4,094.0%-93.7%$5.01MN/A-0.098Analyst RevisionCDTConduit Pharmaceuticals0.2189 of 5 stars$1.57-4.3%N/A-99.4%$4.80MN/A0.003Gap Down Related Companies and Tools Related Companies PPBT Alternatives NKGN Alternatives HCWB Alternatives THAR Alternatives VYNE Alternatives KTTA Alternatives AEZS Alternatives SPRB Alternatives BCTX Alternatives CDT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APVO) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access